ERBB2 and gastroesophageal junction adenocarcinoma: The RATIONALE-305 trial confirmed that in patients with HER2-negative advanced gastric cancer or GEJ adenocarcinoma, tislelizumab combined with chemotherapy significantly improved OS compared with chemotherapy alone (26).